FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
The Food and Drug Administration has granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck cancer whose disease has progressed after platinum-based chemotherapy and immunotherapy.
The decision, announced on 5 November, gives doctors a new option for a group of patients who have run out of standard treatments. It is the first approval in this setting in a decade, and the first time the drug has been approved for a cancer outside the lung.
Rybrevant Faspro, developed by Johnson & Johnson’s Janssen Biotech, is a dual-targeted therapy. It blocks two proteins, EGFR and MET, that can help tumours grow and spread. Unlike the original intravenous version of the drug, it is injected under the skin, which can make treatment quicker and easier to give in a clinic.
What the trial showed
The approval rests on results from cohort 1 of the OrigAMI-4 trial, an open-label, multicentre phase 1b/2 study of 102 adults with recurrent or metastatic head and neck squamous cell carcinoma. All had already received platinum-based chemotherapy and a PD-1 or PD-L1 immunotherapy drug.
In that group, 42% of patients saw their tumours shrink or disappear, a measure known as the overall response rate. Complete responses, where no detectable tumour remained, were seen in 15% of patients. Among those who responded, 56% had a response lasting at least six months.
The results were presented at the 2026 annual meeting of the American Society of Clinical Oncology and published in the Journal of Clinical Oncology.
Who the approval covers — and who it does not
The approval is limited to adults whose cancer has progressed on or after platinum chemotherapy and an anti-PD-(L)1 antibody. It does not cover patients with HPV-associated oropharyngeal cancer, a form of throat cancer linked to the human papillomavirus, as determined by p16 testing.
That distinction matters because HPV-linked throat cancers often behave differently from cancers caused mainly by smoking and alcohol, and they were excluded from the trial that supported the approval.
Because the decision is an accelerated approval, it is based on response rates rather than proof that the drug extends life. Continued approval may depend on a confirmatory study, the phase 3 OrigAMI-5 trial, which is testing Rybrevant Faspro alongside the chemotherapy drug carboplatin and the immunotherapy pembrolizumab as a first treatment for recurrent or metastatic head and neck cancer.
A faster path through the FDA
The application moved quickly through the regulator. The drug received breakthrough therapy designation in February 2026 and priority review in July 2026, two programmes designed to speed up the assessment of medicines for serious conditions where early evidence suggests a meaningful advantage over existing options.
The review was also conducted under Project Orbis, the FDA Oncology Center of Excellence initiative that allows regulators in several countries to assess cancer medicines together.
The approval follows another recent FDA decision on a different medicine, when the agency fast-tracked a sleep drug for children with insomnia, and it sits alongside other recent FDA designations, including orphan-drug status for an experimental treatment for newborn brain injury.
What happens next
For patients, the practical effect is a new second-line option where few existed. Head and neck cancers that return or spread after chemotherapy and immunotherapy have long been among the hardest to treat, and doctors have had little to offer once those therapies stop working.
Johnson & Johnson said the subcutaneous formulation is the first and only dual-targeted therapy approved for advanced head and neck cancer. The company has not said when the treatment will be available in clinics, and pricing has not been disclosed.
The FDA’s full prescribing information will be posted on Drugs@FDA. As with all accelerated approvals, the drug’s place in treatment will depend on the confirmatory trial now under way.
